PPIDT00226
Drug Information
| Name | Ofatumumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP |
| DrugBank_ID | DB06650 |
| Type | biotech |
| Indication | Ofatumumab is indicated, in combination with [chlorambucil], for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.[L12612] In patients with recurrent or progressive CLL, ofatumumab is indicated for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.[L12612] Ofatumumab is indicated for the treatment of patients with CLL refractory to [fludarabine] and [alemtuzumab].[L12612] Ofatumumab is also indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, including active secondary progressive disease, clinically isolated syndrome, and relapsing-remitting disease.[L15581] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
20 mg/1mL
|
| Injection, solution | Intravenous |
20 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Injection, solution, concentrate | Intravenous |
1000 mg
|
| Solution | Intravenous |
100 mg / 5 mL
|
| Solution | Intravenous |
1000 mg / 50 mL
|
| Injection, solution | Intravenous |
100 mg
|
| Injection, solution | Intravenous |
1000 mg
|
| Solution | Intravenous |
20.000 mg
|
| Solution | Subcutaneous |
20.000 mg
|
| Solution | — |
20 mg/0.4mL
|
| Injection, solution | — |
20 mg/0.4ml
|
| Injection, solution | Subcutaneous |
20 MG
|
| Injection, solution | Subcutaneous |
20 mg/0.4mL
|
| Solution | Subcutaneous |
20 mg / 0.4 mL
|
| Solution | Subcutaneous |
5000000 mg
|